PRAX rises as traders refocus on FDA review timeline for ulixacaltamide
Praxis Precision Medicines (PRAX) shares are up about 3.2% Tuesday as investors continue to price in recent FDA progress on its late-stage essential tremor program. The company said April 14, 2026 the FDA accepted its ulixacaltamide NDA, setting a PDUFA target date of Jan. 29, 2027.
1. What’s moving the stock today
Praxis Precision Medicines is trading higher on April 28, 2026, with buying tied to renewed attention on the company’s near- and medium-term regulatory catalysts. The most recent fundamental headline is the FDA’s acceptance of Praxis’ New Drug Application for ulixacaltamide HCl in adults with essential tremor, which put a formal review clock in place and gave investors a clearer timeline to the first potential commercial approval in the franchise. (investors.praxismedicines.com)
2. The catalyst investors are keying on
Praxis disclosed April 14, 2026 that the FDA accepted the ulixacaltamide NDA. That acceptance set a PDUFA target action date of January 29, 2027, and indicated there were no plans to hold an advisory committee meeting, a detail traders often view as a de-risking signal for the review process. (investors.praxismedicines.com)
3. Why the tape can stay sensitive from here
Beyond the essential tremor filing, Praxis has positioned 2026 as a milestone-heavy year across its late-stage CNS pipeline, with additional topline results expected in the first half of 2026 and ongoing pre-launch activities for its NDA-stage assets. With the stock already priced for major outcomes, incremental clarity around regulatory logistics, launch preparation, and upcoming data can continue to drive day-to-day moves even without a fresh press release. (investors.praxismedicines.com)